Treace Medical Concepts stock
TMCINASDAQTreace Medical Concepts, Inc., HealthcareISIN US89455T1097
48Score 48 out of 100, Weak
Price and trend
87 / 100
Price history
+60% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 61% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is at its 52-week high. Largest decline in 6 years: 97% (June 2021 to March 2026).
Chart figures for advanced users
- SMA 50$4.42
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.33
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.20
- The lowest closing price of the last twelve months.
- Resistance$5.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Treace Medical Concepts, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $350.09M, is number 87 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $212.69M (up 1.6% year on year) and a loss of $59M.
- For fiscal 2026, analysts expect on average revenue of $207.88M (down 2.3%) and adjusted earnings per share of −$0.83.
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 406 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 30% a year since 2020, Medical (Devices) median 13.8%.Growth 70
Weaknesses
- DilutionShare count up 24% since 2020.Capital allocation 19
- Loss-makingLoss of $55.79M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 84% a year over the last 12 months.Stability 40
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 7.1% on the twelve months before. Revenue has grown strongly since 2019, at around 32% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 80%, operating −25%, net −28%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 26 Feb 2027in 105 days
- Last reported
- 6 Nov 2026EPS reported −$0.19 (expected −$0.25)above expectations
Analyst estimates
Earnings estimates have barely changed since 29 Oct 2026.
- Earnings per share
- −$0.83+2.4%
- Revenue
- $207.88M+0.2%
- Earnings per share
- −$0.78−1.1%
- Revenue
- $220.72M−0.4%
MEQIRI has stored the estimates since 29 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $1.24M in total.
- Treace John T.Purchase
24 Aug 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 11,000
- Price
- $4.34
- Value
- $47,731
- Treace John T.Purchase
21 Aug 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 5,000
- Price
- $4.35
- Value
- $21,748
- Treace John T.Purchase
20 Aug 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 39,944
- Price
- $4.44
- Value
- $177,176
Show 9 more
- Treace John T.Purchase
11 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 9,891
- Price
- $4.04
- Value
- $39,982
- Treace John T.Purchase
11 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 22,887
- Price
- $4.04
- Value
- $92,541
- Treace John T.Purchase
10 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 14,715
- Price
- $4.02
- Value
- $59,213
- Treace John T.Purchase
10 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 29,430
- Price
- $4.02
- Value
- $118,426
- Treace John T.Purchase
1 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 50,000
- Price
- $3.56
- Value
- $177,915
- Treace John T.Purchase
28 May 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 61,202
- Price
- $3.02
- Value
- $184,824
- Treace John T.Purchase
27 May 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 49,810
- Price
- $2.87
- Value
- $143,189
- Treace John T.Purchase
26 May 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 4,508
- Price
- $2.79
- Value
- $12,576
- Treace John T.Purchase
14 May 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 61,750
- Price
- $2.62
- Value
- $161,495
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Treace Medical Concepts
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- CellaVisionCEVI.ST $483.11M80
- Metall ZugMETN.SW $460.29M40
- Revenio GroupREG1V.HE $419.17M47
- NeuroPaceNPCE $412.58M32
- ImplanticaIMP-A-SDB.ST $400.4M50
- CerusCERS $391.79M33
- StratecSBS.DE $360.32M52
- CapsoVisionCV $333.63M38
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.